Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

Clinical trial NCT05616923 · COMPLETED

Trial details

NCT number: NCT05616923
Sponsor: Albany Research Institute, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Rosacea, Erythematotelangiectatic

Start date: 2021-11-01
Primary completion: 2022-12-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.